tetano
Editor, Senior Moderator
Clin Rheumatol
. 2021 Mar 6.
doi: 10.1007/s10067-021-05675-x. Online ahead of print.
The impact of SARS-CoV-2 coronavirus infection in patients with systemic lupus erythematosus from a single center in Catalonia
Gerard Espinosa[SUP] #[/SUP][SUP] 1 [/SUP], Sergio Prieto-Gonz?lez[SUP] #[/SUP][SUP] 2 [/SUP], Mireia Llevadot[SUP] 3 [/SUP], Javier Marco-Hern?ndez[SUP] 2 [/SUP], Antonio Mart?nez-Artu?a[SUP] 3 [/SUP], Albert P?rez-Isidro[SUP] 4 [/SUP], Elia Rif?[SUP] 3 [/SUP], Ricard Cervera[SUP] 5 [/SUP]
Affiliations
Abstract
Objective: To evaluate the incidence and characteristics of SARS-CoV-2 infection among patients with systemic lupus erythematosus (SLE) and to compare it to that described in the general population.
Methods: For 5 weeks, we carried out a cross-sectional study consisting of telephone interviews of SLE patients. We collected epidemiological data, symptoms suggesting COVID-19, results of nasopharyngeal swabs, and ongoing treatments. In those patients who required hospital admission, clinical, radiological, and laboratory features, and outcome were investigated.
Results: Four hundred patients with SLE completed the survey. Overall, 4 (1.00%, 95%CI 0.02-1.98) patients were classified as confirmed cases of COVID-19 and 26 (6.51%, 95%CI 4.08-8.94) as possible clinical cases. The incidence of confirmed cases in our series was similar to that of the Catalan population (1.00% versus 0.63%; p = 0.456), whereas the incidence of possible cases was higher in our series (6.51% versus 1.29%; p < 0.005). The only difference between SLE patients with confirmed and possible COVID-19 and those without was the percentage of patients who have had contact with a confirmed or possible case of COVID-19 (26.7% versus 9.2%; p = 0.003) CONCLUSIONS: The incidence of COVID-19 in SLE patients with inactive disease is low and, in our series, all cases with confirmed infection recovered. Key Points ? In a cohort of SLE patients with stable and clinical inactive disease, the incidence of COVID-19 is low. ? All SLE patients with confirmed SARS-CoV-2 infection recovered.
Keywords: COVID-19; Hydroxychloroquine; Outbreak; SARS-CoV-2 infection; Systemic lupus
. 2021 Mar 6.
doi: 10.1007/s10067-021-05675-x. Online ahead of print.
The impact of SARS-CoV-2 coronavirus infection in patients with systemic lupus erythematosus from a single center in Catalonia
Gerard Espinosa[SUP] #[/SUP][SUP] 1 [/SUP], Sergio Prieto-Gonz?lez[SUP] #[/SUP][SUP] 2 [/SUP], Mireia Llevadot[SUP] 3 [/SUP], Javier Marco-Hern?ndez[SUP] 2 [/SUP], Antonio Mart?nez-Artu?a[SUP] 3 [/SUP], Albert P?rez-Isidro[SUP] 4 [/SUP], Elia Rif?[SUP] 3 [/SUP], Ricard Cervera[SUP] 5 [/SUP]
Affiliations
- PMID: 33677725
- DOI: 10.1007/s10067-021-05675-x
Abstract
Objective: To evaluate the incidence and characteristics of SARS-CoV-2 infection among patients with systemic lupus erythematosus (SLE) and to compare it to that described in the general population.
Methods: For 5 weeks, we carried out a cross-sectional study consisting of telephone interviews of SLE patients. We collected epidemiological data, symptoms suggesting COVID-19, results of nasopharyngeal swabs, and ongoing treatments. In those patients who required hospital admission, clinical, radiological, and laboratory features, and outcome were investigated.
Results: Four hundred patients with SLE completed the survey. Overall, 4 (1.00%, 95%CI 0.02-1.98) patients were classified as confirmed cases of COVID-19 and 26 (6.51%, 95%CI 4.08-8.94) as possible clinical cases. The incidence of confirmed cases in our series was similar to that of the Catalan population (1.00% versus 0.63%; p = 0.456), whereas the incidence of possible cases was higher in our series (6.51% versus 1.29%; p < 0.005). The only difference between SLE patients with confirmed and possible COVID-19 and those without was the percentage of patients who have had contact with a confirmed or possible case of COVID-19 (26.7% versus 9.2%; p = 0.003) CONCLUSIONS: The incidence of COVID-19 in SLE patients with inactive disease is low and, in our series, all cases with confirmed infection recovered. Key Points ? In a cohort of SLE patients with stable and clinical inactive disease, the incidence of COVID-19 is low. ? All SLE patients with confirmed SARS-CoV-2 infection recovered.
Keywords: COVID-19; Hydroxychloroquine; Outbreak; SARS-CoV-2 infection; Systemic lupus